Continuous manufacturing presents a transformative approach to pharmaceutical production, yet it faces numerous challenges that hinder widespread adoption. Despite the potential benefits, traditional batch manufacturing continues to dominate the landscape.
The State of Continuous Manufacturing
At an event held on May 6, 2019, at St. John’s University, experts discussed the current standing of continuous pharmaceutical manufacturing. With over 20 products pending FDA review utilizing this approach, the technology’s economic viability remains a major concern, especially for generic pharmaceutical manufacturers. Atul Dubey, director of pharmaceutical continuous manufacturing at the United States Pharmacopeia (USP), emphasized the lack of compelling financial incentives for generics to invest in continuous processes.
Ajaz Hussain, a prominent consultant in the field and former head of the FDA’s Office of Pharmaceutical Sciences, highlighted that while continuous manufacturing could enhance supply chain reliability and mitigate medication shortages, the fragmented nature of the generics market complicates its implementation. He noted that if an original product was not developed using continuous manufacturing, generic producers often lack incentive to adopt the same approach.
The Role of External Manufacturing Hubs
Hussain forecasts the emergence of external manufacturing hubs based at universities and contract development organizations (CDMOs) to facilitate continuous manufacturing for the pharmaceutical industry. These hubs could serve as a bridge, providing the necessary expertise and resources for generics companies to transition towards continuous processes.
A critical component of this transition is the need for “new prior knowledge” (NPK). This involves sharing essential information regarding quality issues and potential failure modes with generic manufacturers. By granting access to NPK, companies can better understand the relationship between drug characteristics and product performance, ultimately leading to quicker development timelines and regulatory reviews.
The Evolution of Quality Control
As the industry progresses, there is a significant shift towards advanced process control strategies. The concept of pharmaceutical quality by design (QbD) is evolving into “quality by control,” emphasizing the importance of feedback mechanisms in maintaining product quality. Zoltan Nagy from Purdue University articulated the need for critical quality attributes to be adjustable, allowing for a more dynamic response to variations in the manufacturing process.
The integration of process analytical technology (PAT) tools is crucial in this evolution. Historically underutilized for feedback control, these tools are now being developed to enhance process understanding and maintain product quality. Continuous monitoring and data reconciliation can help manage critical quality attributes, ensuring consistency in output regardless of input fluctuations.
Industry Case Studies: Big Pharma’s Approach
Leading pharmaceutical companies are actively exploring continuous manufacturing strategies. Takeda Pharmaceuticals, for instance, has built upon Shire Pharma’s continuous manufacturing competencies since its acquisition. The company is currently investigating continuous processes for both encapsulation and tableting, aiming to streamline production for medications like Vyvanse.
Merck has also engaged in pilot projects to leverage continuous manufacturing, focusing on real-time release testing and quality by design. Their goal is to produce nearly one billion tablets annually with significantly reduced lead times. The implementation of continuous processes offers potential efficiency gains, but Merck acknowledges that a combination of batch and continuous methods may ultimately be more beneficial.
The Complexities of Scaling Up
Michael Rooney from Genesis Engineers addressed the difficulties associated with scaling up continuous manufacturing. Transitioning from batch to continuous processes involves not only technical challenges but also significant financial considerations. Facilities must accommodate new workflows, which may require substantial modifications to existing infrastructure.
Rooney’s case studies illustrated that investing in continuous manufacturing often raises concerns about return on investment. Companies must balance the costs of skilled labor and new technology against the potential benefits of increased efficiency. The complexity of integrating continuous systems into established facilities cannot be underestimated; it demands careful planning and resource allocation.
USP’s Role in Facilitating Adoption
The USP is taking proactive steps to standardize methodologies for continuous manufacturing, particularly in the generics sector. Atul Dubey highlighted the need for practical solutions to facilitate adoption among latecomers. By developing new standards and educational resources, the USP aims to streamline the transition and promote quality across all manufacturing processes.
The Vision for End-to-End Continuous Manufacturing
Bayan Takizawa from Continuus Pharmaceuticals discussed ongoing projects aimed at achieving end-to-end continuous manufacturing from active pharmaceutical ingredients (APIs) to finished products. He emphasized that a thorough understanding of critical process parameters and their management is essential for successful implementation.
While advancements in continuous manufacturing show promise, challenges remain. Industry inertia and the need for skilled technical support are significant barriers to widespread adoption. Successful integration of continuous processes necessitates collaboration between equipment vendors, regulatory bodies, and manufacturers to ensure that innovative technologies are embraced.
Conclusion
The journey towards widespread adoption of continuous manufacturing in pharmaceuticals is fraught with challenges, yet the potential rewards are substantial. As the industry navigates these complexities, collaboration and innovation will be vital. Through shared knowledge and strategic partnerships, continuous manufacturing can evolve from a promising concept to a standard practice, reshaping the future of pharmaceutical production.
- Continuous manufacturing offers efficiency and reliability benefits but faces economic barriers for generics.
- External manufacturing hubs may bridge the expertise gap for pharmaceutical companies.
- The shift towards advanced process control emphasizes flexibility in maintaining product quality.
- Scaling up continuous processes involves substantial infrastructure and financial considerations.
- Regulatory bodies like USP play a crucial role in facilitating the transition to continuous manufacturing.
Source: www.pharmtech.com